Bayer's Development of Vardenafil for ED Treatment
)Tj 0 Tc -0.0006 Tw -0.78 -1.655 Td (Back pain was reported in 2.0% of patients treated)Tj 0 Tw ( with LEVITRA and 1.7% of patients on placebo. )Tj 0.0001 Tc -0.0026 Tw 0 -1.315 TD (Placebo-controlled trials suggested )Tj 0.0002 Tc -0.001 Tw 14.25 0 Td (a dose effect in the incidence of)Tj 0.0004 Tc -0.0016 Tw 12.71 0 Td [( som)8.2 (e)-0.8 ( adverse events \(headache, )]TJ -0.0003 Tw -26.96 -1.15 Td (flushing, dyspepsia, nausea, rhinitis\) over the )Tj 0.0001 Tc 0.0004 Tw 18.37 0 Td [(5 mg, 10 m)7.9 (g, and 20 m)7.9 (g doses of LEVITRA.
More from this author
It is a dopamine receptor agonist and works through an entirely different mechanism. Although the drug received the support of an FDA advisory panel in April 2000 (as reported by heartwire ), TAP Pharmaceuticals withdrew apomorphine's new drug application soon after, due to concerns that it caused fainting spells. It resubmitted the drug late last year after further studies. Cite this: FDA approves new erectile dysfunction drug - Medscape - Aug 20, 2003. aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction levitra generic quality The potential value of erectile dysfunction inquiry and management Hellstrom, W.
A comprehensive review of erectile dysfunction in men with diabetes
∙ Gittelman, M. ∙ Karlin, G. ..., on behalf of the Vardenafil Study Group Sustained efficacy and tolerability of vardenafil (Levitra®), a highly potent, selective phosphodiesterase-5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Wie wirksam sind die PDE-5 Hemmstoffe When an erection alone is not enough: biopsychosocial obstacles to lovemaking Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users Drop out reason in responders to sildenafil Size of this preview: 800 × 571 pixels. Other resolutions: 320 × 229 pixels 640 × 457 pixels. The )]TJ 0.0008 Tc -0.0018 Tw -18.37 -1.15 Td [(f)3.8 (o)0.8 (llowing se)4.6 (ction identif)3.8 (i)-1.4 (es add)5.8 (ition)5.8 (a)4.6 (l, less f)3.8 (r)-1.2 (equ)5.8 (e)]TJ 0.001 Tc 19.99 0 Td [(nt events \(<)5 (2%\) repo)6 (rte)4.8 (d)1 ( during th)6 (e clin)6 (ical )]TJ 0.0006 Tc -0.002 Tw -19.99 -1.15 Td [(developm)8.4 (ent of LEVITRA.
- Levitra 20 mg Bayer can be part of a comprehensive ED management plan.
- Regular check-ups are recommended for users on this medication.
- Discontinue use and seek medical advice if adverse reactions occur.
- Levitra may be ineffective if taken with high-fat meals.
- Use with caution if you have any bleeding or clotting disorders.
- The medication may interact with certain antifungal and antibiotic drugs.
- Patients should inform their doctor about all current medications.
- Timing of medication can influence the success of treatment.
- Levitra 20 mg Bayer does not cause addiction or dependency.
- The drug is often preferred for its rapid onset of action.
- It’s important to have realistic expectations about the results.
Excluded from)8.4 ( this list ar)]TJ -0.0027 Tw 21.44 0 Td [(e those events that are infrequ)5.6 (e)4.4 (nt and m)8.4 (i)-1.6 (nor, )]TJ 0.0003 Tc -0.0009 Tw -21.44 -1.145 Td [(those events that m)8.1 (a)-0.9 (y be commonly observed in the )]TJ 0.0001 Tc -0.0013 Tw (absence of drug therapy, a)Tj 0.0003 Tc -0.0015 Tw 31.49 0 Td (nd those events that are )Tj -0.0001 Tc 0.0001 Tw -31.49 -1.155 Td (not reasonably associated with the drug. )Tj 0 Tc 0.0037 Tw 1.5 -1.315 Td (BODY AS A WHOLE: anaphylactic)Tj 0.0008 Tc -0.0015 Tw 14.775 0 Td [( reaction \(in)5.8 (cluding lary)5.8 (ngeal edem)8.6 (a\), asthen)5.8 (ia, f)8.8 (ace edem)8.6 (a, )]TJ 0.0009 Tc 0 Tw -14.775 -2.3 Td (pain )Tj 0.0004 Tc -0.0004 Tw 0 -2.805 TD [(AUDITOR)-2.6 (Y)2.6 (: tinnitus )]TJ -0.0003 Tc 0.0003 Tw 0 -1.31 TD [(CARDIOVASCULAR:)-7.5 ( angina pectoris, ches)]TJ 0.0003 Tc -0.0003 Tw 18.11 0 Td [(t pain, hypertension, hypotension, m)8.1 (yocardial )]TJ 0.0005 Tc -0.0005 Tw -18.11 -1.155 Td [(ischem)8.3 (ia, myocardial inf)8.5 (a)-0.7 (rction, palpitation, )]TJ -0.0001 Tc 0.0001 Tw 17.97 0 Td (postural hypotension, s)Tj 0 Tc 0 Tw 9.245 0 Td (yncope, tachycardia )Tj 0.0002 Tc -0.0002 Tw -27.215 -1.31 Td [(DIGESTIVE: abdom)8 (inal pain, abnorm)8 (al liver f)]TJ -0.0027 Tw 18.88 0 Td [(unction tests, diarrhea, dry )-7.5 (m)8 (outh, dysphagia, )]TJ 0.0005 Tc -0.003 Tw -18.88 -1.155 Td [(esophagitis, gastritis, gas)4.7 (t)-1.7 (roesophag)5.5 (e)]TJ 0.0006 Tc -0.0006 Tw 14.83 0 Td [(al reflux, G)7.8 (G)2.8 (TP increas)4.8 (ed, vom)8.4 (iting )]TJ 0.0004 Tc -0.0004 Tw -14.83 -1.32 Td (MUSCULOSKELETAL: arthra)Tj 0.0005 Tc -0.0025 Tw 12.805 0 Td (lgia, back pain, myalgia, neck pain )Tj 0.0001 Tc -0.0017 Tw -12.805 -1.315 Td [(NERVOUS:)-7.1 ( hypertonia, hypesthesia, insom)7.9 (nia)]TJ 0.0002 Tc 18.855 0 Td [(, paresthesia, som)8 (nolence, vertigo )]TJ 0.0004 Tc -0.0004 Tw -18.855 -1.315 Td (RESPIRATORY: dyspnea, ep)Tj -0.0003 Tc 0.0003 Tw 12.09 0 Td (istaxis, pharyngitis )Tj 0 Tc 0.0016 Tw -12.09 -1.32 Td (SKIN AND APPENDAGES: photosensitivity)Tj 0.0002 Tc -0.0014 Tw 18.42 0 Td ( reaction, pruritus, rash, sweating )Tj ET q 1 0 0 1 -8.195038 -34.037292 cm /CS0 CS 0.004 0.004 0.004 SCN 0.75 w 1 j 1 J q 1 0 0 1 61.2 652.08 cm 0 0 m 432 0 l 0.48 -22.68 m 432.48 -22.68 l 0.48 -60.3 m 432.48 -60.3 l 0 -203.7 m 432 -203.7 l S Q Q /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 201 0 obj <>>>/Resources 234 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 202 0 obj <>>>/Resources 236 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 236 0 obj <> endobj 237 0 obj <> endobj 235 0 obj <>stream �5H�8CTzd#E���[��w���ᮆ�)ȼ�7�)��ࢠ1�97���8�������{�s ��~�N�4T$�C#A�}�A�_��r�y���XXm�d�=��jc����}�jˇX���(��? Proportion of vardenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo after repeated usedate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Mean sperm concentrationdate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Mean sperm countdate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Proportion of sildenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo and vardenafil after repeated usedate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Washington, DC - The FDA gave approval yesterday to vardenafil (Levitra®, Bayer and Glaxo Smith Kline), an oral erectile-dysfunction drug that works through the same mechanism as sildenafil (Viagra®, Pfizer).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Levitra Professional | 20mg | 270 + 6 Pills | 738.98€ 703.79€ | |
| Levitra Generic | 60mg | 60 + 4 Pills | 198.85€ 189.38€ | |
| Levitra Original | 20mg | 76 + 4 Pills | 344.39€ 327.99€ | |
| Levitra Original | 20mg | 22 + 2 Pills | 138.55€ 131.95€ | |
| Levitra Generic | 40mg | 20 Pills | 67.56€ 64.34€ | |
| Levitra Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Levitra Original | 20mg | 12 Pills | 81.99€ 78.09€ | |
| Levitra Generic | 20mg | 30 + 4 Pills | 70.59€ 67.23€ | |
| Levitra Generic | 10mg | 60 + 6 Pills | 112.98€ 107.60€ | |
| Levitra Soft Tabs | 20mg | 180 + 10 Pills | 398.14€ 379.18€ | |
| Levitra Professional | 20mg | 120 + 4 Pills | 348.44€ 331.85€ | |
| Levitra Original | 20mg | 4 Pills | 45.87€ 43.69€ | |
| Levitra Generic | 40mg | 360 + 10 Pills | 704.99€ 671.42€ |
Like sildenafil, vardenafil can seriously affect blood pressure and should not be taken by those on alpha blockers or nitrates. The recommended dose is 10 mg taken one hour before sexual activity, with 20-, 5.0-, and 2.5-mg doses available.
See also:
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy
Vardenafil is a phosphodiesterase inhibitor and, like sildenafil, is strongly contraindicated if patients are taking nitrates (nitroglycerin tablets or patches) or alpha blockers, due to the possibility of a steep drop in blood pressure. Patients with QT prolongation are also advised not to take the drug, as buy levitra no prescription there is a possibility of abnormal heart rhythm in these patients. The FDA warns that men whose underlying cardiovascular status makes sexual activity inadvisable should not take vardenafil.
| Region | Price Range (per tablet) | Available Brands |
|---|---|---|
| North America | $10 - $25 | Bayer, Generic versions |
| Europe | €8 - €20 | Bayer, Generics |
| Asia | $5 - $15 | Bayer, Local generic brands |
| Australia | AUD 15 - AUD 35 | Bayer, Other authorized generics |
Patients who have suffered an MI or stroke within the last six months or have hypotension or hypertension, unstable angina, severe liver impairment, end-stage renal disease requiring dialysis, or retinitis pigmentosa should not take the drug.
Primary Outcome
Original file (840 × 600 pixels, file size: 24 KB, MIME type: image/jpeg) From Wikimedia Commons, the free media repository Size of this preview: 800 × 571 pixels. Original file (840 × 600 pixels, file size: 24 KB, MIME type: image/jpeg) Click on a date/time to view the file as it appeared at that time. There are no pages that use this file. The following other wikis use this file: The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dosedate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)date_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mgdate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue:
ScriptSave WellRx
"Today's approval of Levitra means there is now an important alternative in the treatment of erectile dysfunction," said Colin J Foster, president, Bayer Pharmaceuticals Corporation, in a press release. The drug will be comarketed by Glaxo Smith Kline and Bayer, and Bloomberg News reports packaging will feature the "Levitra flame" to help distinguish the round orange pills from Viagra's now-famous blue diamond-shaped ones.
- Levitra 20 mg Bayer is popular for its reliability and quick action.
- It’s important to read the patient information leaflet thoroughly.
- This medication is not suitable for children or minors.
- Levitra can sometimes cause a drop in blood pressure.
- Do not combine Levitra with recreational drugs like poppers.
- Men should avoid alcohol for optimal medication efficacy.
- Levitra 20 mg Bayer may be part of a broader cardiovascular assessment.
- Sexual activity should only be undertaken when fully prepared.
- Abstain from heavy physical activity immediately after taking the pill.
- Levitra does not cure underlying causes of erectile dysfunction.
- Always consult a healthcare professional for persistent ED symptoms.
Both drugs are likely to soon have a third competitor stateside. Eli Lilly & Co and Icos Corporation intend to introduce tadalafil (Cialis®), another phosphodiesterase inhibitor, to the US market later this year. Tadalafil and vardenafil have both been approved in Europe.
Key Participants Requirements
)Tj 0 Tc -0.0006 Tw -0.78 -1.655 Td (Back pain was reported in 2.0% of patients treated)Tj 0 Tw ( with LEVITRA and 1.7% of patients on placebo. )Tj 0.0001 Tc -0.0026 Tw 0 -1.315 TD (Placebo-controlled trials suggested )Tj 0.0002 Tc -0.001 Tw 14.25 0 Td (a dose effect in the incidence of)Tj 0.0004 Tc -0.0016 Tw 12.71 0 Td [( som)8.2 (e)-0.8 ( adverse events \(headache, )]TJ -0.0003 Tw -26.96 -1.15 Td (flushing, dyspepsia, nausea, rhinitis\) over the )Tj 0.0001 Tc 0.0004 Tw 18.37 0 Td [(5 mg, 10 m)7.9 (g, and 20 m)7.9 (g doses of LEVITRA. The )]TJ 0.0008 Tc -0.0018 Tw -18.37 -1.15 Td [(f)3.8 (o)0.8 (llowing se)4.6 (ction identif)3.8 (i)-1.4 (es add)5.8 (ition)5.8 (a)4.6 (l, less f)3.8 (r)-1.2 (equ)5.8 (e)]TJ 0.001 Tc 19.99 0 Td [(nt events \(<)5 (2%\) repo)6 (rte)4.8 (d)1 ( during th)6 (e clin)6 (ical )]TJ 0.0006 Tc -0.002 Tw -19.99 -1.15 Td [(developm)8.4 (ent of LEVITRA. Excluded from)8.4 ( this list ar)]TJ -0.0027 Tw 21.44 0 Td [(e those events that are infrequ)5.6 (e)4.4 (nt and m)8.4 (i)-1.6 (nor, )]TJ 0.0003 Tc -0.0009 Tw -21.44 -1.145 Td [(those events that m)8.1 (a)-0.9 (y be commonly observed in the )]TJ 0.0001 Tc -0.0013 Tw (absence of drug therapy, a)Tj 0.0003 Tc -0.0015 Tw 31.49 0 Td (nd those events that are )Tj -0.0001 Tc 0.0001 Tw -31.49 -1.155 Td (not reasonably associated with the drug. )Tj 0 Tc 0.0037 Tw 1.5 -1.315 Td (BODY AS A WHOLE: anaphylactic)Tj 0.0008 Tc -0.0015 Tw 14.775 0 Td [( reaction \(in)5.8 (cluding lary)5.8 (ngeal edem)8.6 (a\), asthen)5.8 (ia, f)8.8 (ace edem)8.6 (a, )]TJ 0.0009 Tc 0 Tw -14.775 -2.3 Td (pain )Tj 0.0004 Tc -0.0004 Tw 0 -2.805 TD [(AUDITOR)-2.6 (Y)2.6 (: tinnitus )]TJ -0.0003 Tc 0.0003 Tw 0 -1.31 TD [(CARDIOVASCULAR:)-7.5 ( angina pectoris, ches)]TJ 0.0003 Tc -0.0003 Tw 18.11 0 Td [(t pain, hypertension, hypotension, m)8.1 (yocardial )]TJ 0.0005 Tc -0.0005 Tw -18.11 -1.155 Td [(ischem)8.3 (ia, myocardial inf)8.5 (a)-0.7 (rction, palpitation, )]TJ -0.0001 Tc 0.0001 Tw 17.97 0 Td (postural hypotension, s)Tj 0 Tc 0 Tw 9.245 0 Td (yncope, tachycardia )Tj 0.0002 Tc -0.0002 Tw -27.215 -1.31 Td [(DIGESTIVE: abdom)8 (inal pain, abnorm)8 (al liver f)]TJ -0.0027 Tw 18.88 0 Td [(unction tests, diarrhea, dry )-7.5 (m)8 (outh, dysphagia, )]TJ 0.0005 Tc -0.003 Tw -18.88 -1.155 Td [(esophagitis, gastritis, gas)4.7 (t)-1.7 (roesophag)5.5 (e)]TJ 0.0006 Tc -0.0006 Tw 14.83 0 Td [(al reflux, G)7.8 (G)2.8 (TP increas)4.8 (ed, vom)8.4 (iting )]TJ 0.0004 Tc -0.0004 Tw -14.83 -1.32 Td (MUSCULOSKELETAL: arthra)Tj 0.0005 Tc -0.0025 Tw 12.805 0 Td (lgia, back pain, myalgia, neck pain )Tj 0.0001 Tc -0.0017 Tw -12.805 -1.315 Td [(NERVOUS:)-7.1 ( hypertonia, hypesthesia, insom)7.9 (nia)]TJ 0.0002 Tc 18.855 0 Td [(, paresthesia, som)8 (nolence, vertigo )]TJ 0.0004 Tc -0.0004 Tw -18.855 -1.315 Td (RESPIRATORY: dyspnea, ep)Tj -0.0003 Tc 0.0003 Tw 12.09 0 Td (istaxis, pharyngitis )Tj 0 Tc 0.0016 Tw -12.09 -1.32 Td (SKIN AND APPENDAGES: photosensitivity)Tj 0.0002 Tc -0.0014 Tw 18.42 0 Td ( reaction, pruritus, rash, sweating )Tj ET q 1 0 0 1 -8.195038 -34.037292 cm /CS0 CS 0.004 0.004 0.004 SCN 0.75 w 1 j 1 J q 1 0 0 1 61.2 652.08 cm 0 0 m 432 0 l 0.48 -22.68 m 432.48 -22.68 l 0.48 -60.3 m 432.48 -60.3 l 0 -203.7 m 432 -203.7 l S Q Q /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 201 0 obj <>>>/Resources 234 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.
J. Urol.
) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 202 0 obj <>>>/Resources 236 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 236 0 obj <> endobj 237 0 obj <> endobj 235 0 obj <>stream �5H�8CTzd#E���[��w���ᮆ�)ȼ�7�)��ࢠ1�97���8�������{�s ��~�N�4T$�C#A�}�A�_��r�y���XXm�d�=��jc����}�jˇX���(��? Proportion of vardenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo after repeated usedate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Mean sperm concentrationdate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Mean sperm countdate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Proportion of sildenafil subjects with a 50% or greater decrease from baseline in mean sperm concentration at 6 months (LOCF), compared to placebo and vardenafil after repeated usedate_rangeTime Frame:24 weeksenhanced_encryptionyesSafety Issue: Washington, DC - The FDA gave approval yesterday to vardenafil (Levitra®, Bayer and Glaxo Smith Kline), an oral erectile-dysfunction drug that works through the same mechanism as sildenafil (Viagra®, Pfizer). Like sildenafil, vardenafil can seriously affect blood pressure and should not be taken by those on alpha blockers or nitrates. The recommended dose is 10 mg taken one hour before sexual activity, with 20-, 5.0-, and 2.5-mg doses available. Vardenafil is a phosphodiesterase inhibitor and, like sildenafil, is strongly contraindicated if patients are taking nitrates (nitroglycerin tablets or patches) or alpha blockers, due to the possibility of a steep drop in blood pressure. Currently, there have been no head-to-head trials comparing effectiveness of the three drugs.
Frequently asked questions
A fourth oral erectile-dysfunction drug, apomorphine (Uprima®, TAP Pharmaceuticals), has been approved in Europe, and TAP Pharmaceuticals applied to the FDA for its approval at the end of 2002.
Study design
Patients with QT prolongation are also advised not to take the drug, as buy levitra no prescription there is a possibility of abnormal heart rhythm in these patients. The FDA warns that men whose underlying cardiovascular status makes sexual activity inadvisable should not take vardenafil. Patients who have suffered an MI or stroke within the last six months or have hypotension or hypertension, unstable angina, severe liver impairment, end-stage renal disease requiring dialysis, or retinitis pigmentosa should not take the drug. "Today's approval of Levitra means there is now an important alternative in the treatment of erectile dysfunction," said Colin J Foster, president, Bayer Pharmaceuticals Corporation, in a press release. The drug will be comarketed by Glaxo Smith Kline and Bayer, and Bloomberg News reports packaging will feature the "Levitra flame" to help distinguish the round orange pills from Viagra's now-famous blue diamond-shaped ones.
Clin. Endocrinol. (Oxf)
Both drugs are likely to soon have a third competitor stateside. Eli Lilly & Co and Icos Corporation intend to introduce tadalafil (Cialis®), another phosphodiesterase inhibitor, to the US market later this year. Tadalafil and vardenafil have both been approved in Europe. Currently, there have been no head-to-head trials comparing effectiveness of the three drugs. A fourth oral erectile-dysfunction drug, apomorphine (Uprima®, TAP Pharmaceuticals), has been approved in Europe, and TAP Pharmaceuticals applied to the FDA for its approval at the end of 2002. It is a dopamine receptor agonist and works through an entirely different mechanism.
| Condition | Description | Recommended use |
|---|---|---|
| Erectile Dysfunction | Difficulty in achieving or maintaining an erection | As prescribed by a doctor |
| Pulmonary Arterial Hypertension | Off-label use in some cases | Not approved without supervision |
| Menopause-related Sexual Dysfunction | Experimental treatment | Not approved officially |
Although the drug received the support of an FDA advisory panel in April 2000 (as reported by heartwire ), TAP Pharmaceuticals withdrew apomorphine's new drug application soon after, due to concerns that it caused fainting spells. It resubmitted the drug late last year after further studies. Cite this: FDA approves new erectile dysfunction drug - Medscape - Aug 20, 2003. aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction levitra generic quality The potential value of erectile dysfunction inquiry and management Hellstrom, W. ∙ Gittelman, M. ∙ Karlin, G. ..., on behalf of the Vardenafil Study Group Sustained efficacy and tolerability of vardenafil (Levitra®), a highly potent, selective phosphodiesterase-5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Wie wirksam sind die PDE-5 Hemmstoffe When an erection alone is not enough: biopsychosocial obstacles to lovemaking Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users Drop out reason in responders to sildenafil Size of this preview: 800 × 571 pixels. Other resolutions: 320 × 229 pixels 640 × 457 pixels. Original file (840 × 600 pixels, file size: 24 KB, MIME type: image/jpeg) From Wikimedia Commons, the free media repository Size of this preview: 800 × 571 pixels. Original file (840 × 600 pixels, file size: 24 KB, MIME type: image/jpeg) Click on a date/time to view the file as it appeared at that time. There are no pages that use this file. The following other wikis use this file: The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dosedate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)date_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mgdate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue:
| Advice | Explanation |
|---|---|
| Avoid alcohol | Can decrease effectiveness or increase side effects |
| Do not take with fatty meals | May delay absorption |
| Report adverse effects | Seek medical attention for prolonged erection or vision changes |
| Follow prescribed dose | Do not alter dose without consulting healthcare professional |